Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Retatrutide (LY3437943) is a novel triple-hormone-receptor agonist developed by researchers at Eli Lilly and Company [11]
From a cost-effectiveness perspective, these drugs would have to translate to striking long-term health benefits for patients, such as a reduction in major cardiac events or an overall increase in time to dialysis
A portion of these patients were prescribed semaglutide
When used with insulin or sulfonylureas, there is an increased risk of hypoglycaemia (low blood sugar), and dose reductions of these medications may be needed
US$ 27.56
US$ 28.78
US$ 29.06
US$ 26.36
US$ 20.92
US$ 28.20
US$ 22.42
